DZ BANK upgraded QIAGEN (ETR:QIA) to Buy in a report released earlier today.
- Updated: September 16, 2016
Just yesterday QIAGEN (ETR:QIA) traded 0.00% even at 22.92EUR. The company’s 50-day moving average is 0.00EUR and its 200-day average is 0.00EUR. The last stock close is up 0.00% from the two hundred day moving average, compared with the Standard & Poor’s 500 Index which has fallen -0.01% over the date range. Volume of trade was held steady, with 0 shares of QIA changing hands on par with the typical 0 shares..
DZ BANK has upgraded QIAGEN(ETR:QIA) to Buy in a report released 9/13/2016.
Previously on 9/12/2016, BNP PARIBAS released a statement for QIAGEN(ETR:QIA) upped the target price from 0.00EUR to 18.50EUR. At the time, this suggested a downside of -0.19%.
QIAGEN has a 52 week low of 0.00EUR and a one-year high of 0.00EUR . The company’s total market value is currently 0.0 EUR.
General Information About QIAGEN (ETR:QIA)
QIAGEN N.V. (QIAGEN) is a holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems. Its bioinformatics solutions interpret data to provide actionable insights. Its automation platforms tie these together in molecular testing workflows-from Sample to Insight. Its Sample to Insight molecular technologies are applicable across a range of applications and customer classes through over 500 core consumable products, as well as instruments that automate the use of these products for sample preparation, analysis and interpretation. Its bioinformatics solutions connect laboratory workflows and process amounts of genomic data, enabling scientists or clinicians to decide on further action. It offers solutions in molecular diagnostics, applied testing, and pharma and academia.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.